



---

Erskine, RM and Degens, H (2013) Muscle Growth, Repair and Preservation: A Mechanistic Approach. In: Nutrition and Enhanced Sports Performance. Elsevier, pp. 247-263. ISBN 0123964776

---

**Downloaded from:** <https://e-space.mmu.ac.uk/619563/>

**Version:** Accepted Version

**Publisher:** Elsevier

**DOI:** <https://doi.org/10.1016/B978-0-12-396454-0.00025-4>

Please cite the published version

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/321685438>

# Muscle Growth, Repair and Preservation: A Mechanistic Approach

Chapter · December 2017

CITATIONS

0

2 authors:



**Robert M. Erskine**

Liverpool John Moores University

43 PUBLICATIONS 452 CITATIONS

[SEE PROFILE](#)



**Hans Degens**

Manchester Metropolitan University

186 PUBLICATIONS 3,682 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



The genetic association with exercise-induced muscle damage [View project](#)



Genetics of Sarcopenia [View project](#)

## **Muscle Growth, Repair and Preservation: A Mechanistic Approach**

Robert M. Erskine<sup>1,2</sup> and Hans Degens<sup>3,4</sup>

*<sup>1</sup>School of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom; <sup>2</sup>Institute of Sport, Exercise and Health, Division of Surgery and Interventional Sciences, University College London, London, UK; <sup>3</sup>School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom; <sup>4</sup>Institute of Sport Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania.*

**Address correspondence to:** R.M. Erskine, PhD; School of Sport and Exercise Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, United Kingdom; Tel: +44 (0)151 904 6256; Fax: +44 (0)151 904 6284; Email: R.M.Erskine@ljmu.ac.uk

**Running title:** Muscle Growth, Repair and Preservation

## **SUMMARY**

Resistance exercise, amino acid ingestion and an anabolic hormone environment all have the capacity to elevate muscle protein synthesis (MPS), while a catabolic hormone environment, such as elevated pro-inflammatory cytokines as seen during disuse, aging, and conditions such as cancer and AIDS, can cause an increase in muscle protein degradation (MPD). When the rate of MPS exceeds that of MPD there is a positive net protein balance (NPB) and over a prolonged period of time this results in accretion of contractile material and muscle growth, or hypertrophy. In contrast, when NPB is chronically negative, muscle atrophy occurs, i.e. muscle size decreases. Various signaling pathways within the muscle fiber appear to play a crucial role in the adaptive processes, and understanding how these pathways can be modulated will help the design of therapies to prevent or reverse muscle atrophy in a host of muscle wasting conditions.

**Key words:** skeletal muscle – protein synthesis – hypertrophy – atrophy – IGF-I – mTOR – cytokine – TNF- $\alpha$  – interleukin – myostatin

## INTRODUCTION

Skeletal muscle comprises numerous bundles of long, thin, multinucleated cells called muscle fibers, each containing a multitude of myofibrils. Each myofibril is composed of myofilaments (comprising the contractile proteins, actin and myosin) and a variety of structural proteins, all arranged in a regular configuration throughout the length of the myofibril, so as to form a series of contractile components, or sarcomeres. The maximum force that can be generated by a muscle fiber is proportional to the number of sarcomeres arranged in parallel, or fiber cross-sectional area (CSA), and ultimately the CSA of the whole muscle (Jones, Rutherford, Parker, 1989). Therefore, there is a strong relationship between whole muscle CSA and maximum isometric force measured *in vivo* (Bamman, Newcomer, Larson-Meyer, Weinsier, Hunter, 2000; Fukunaga et al., 2001; Kanehisa, Ikegawa, Fukunaga, 1994).

Based on the relationship between muscle size and force generating capacity (Erskine, Fletcher, Folland, 2014), it is not surprising that an increase in muscle size following resistance training (RT) is accompanied by an increase in maximal muscle force (Erskine, Jones, Williams, Stewart, Degens, 2010b; Jones, Rutherford, 1987; Narici et al., 1996). Not only can this enhance the athletic performance of an individual but it can also reduce the elevated risk of falling and bone fracture in older people that is among other factors attributable to sarcopenia (the age-related loss of muscle mass). The question thus arises as to the mechanisms underlying overload-induced muscle hypertrophy.

A multitude of signaling molecules within the muscle fiber are thought to play an integral role in stimulating muscle protein synthesis (MPS) and degradation (MPD). If

there is a positive net protein balance (NPB), i.e. when the rate of MPS exceeds that of MPD, the amount of contractile material will increase, enabling the muscle to hypertrophy and generate more force. Conversely, when NPB is negative, the muscle will decrease in size, or atrophy, and become weaker. This chapter will explore the specific signaling pathways involved in MPS and MPD, which help to explain how skeletal muscle adapts to overload, disuse, ageing and muscle-wasting diseases. Furthermore, strategies used to preserve or maintain muscle mass during periods of disuse and wasting, such as RT and nutritional interventions, will be discussed.

In addition to the mechanisms underlying muscle growth and atrophy, there is still more to be learned about the systems associated with repair following exercise-induced muscle damage. Several studies have reported that disruption of the cytoskeletal structure of muscle fibers is accompanied by impairment of muscular function following damage-inducing exercise (Baumert, Lake, Stewart, Drust, Erskine, 2016; Friden, Sjöström, Ekblom, 1983; Lieber, Shah, Friden, 2002). As well as structural damage to the sarcomere, eccentric exercise can cause raised intracellular calcium ion ( $\text{Ca}^{2+}$ ) levels (Belcastro, Albisser, Littlejohn, 1996), decreased muscle force production (Clarkson, Sayers, 1999; Friden et al., 1983), an increase in serum levels of muscle-specific proteins (Ebbeling, Clarkson, 1989), an increase in muscle specific inflammation (MacIntyre, Reid, McKenzie, 1995), an increase in proteolytic enzyme activity (Evans, Cannon, 1991), and a delayed-onset muscle soreness (MacIntyre et al., 1995). The ultimate repair of the muscle requires the activation of satellite cells and in this chapter we will consider the various MPD systems and the role of satellite cells thought to play a major role in muscle damage and repair following exercise.

## MUSCLE GROWTH

While prenatal muscle growth is largely the result of muscle fiber formation, postnatal maturational muscle growth and that in response to RT is almost entirely attributable to fiber hypertrophy. Prenatal myogenesis, i.e. the formation of muscle fibers during embryonic development, involves the proliferation, migration, differentiation and fusion of muscle precursor cells to form post-mitotic multinucleated myotubes. Postnatal skeletal muscle growth is accompanied by an increase in the number of myonuclei per muscle fiber (Delhaas, van der Meer, Schaart, Degens, Drost, In Press) that requires the activation of muscle stem cells, or satellite cells (located at the basal lamina that surrounds the muscle fiber), which proliferate and fuse with existing muscle fibers (Jacquemin, Furling, Bigot, Butler-Browne, Mouly, 2004). Once fully mature, skeletal muscle growth, or hypertrophy, is dependent upon a positive NPB, i.e. MPS must be greater than MPD (Chesley, MacDougall, Tarnopolsky, Atkinson, Smith, 1992; Phillips, Tipton, Aarsland, Wolf, Wolfe, 1997), a process that is driven by an increase in the rate of MPS (Kumar, Atherton, Smith, Rennie, 2009). This leads to an accretion of myofibrillar proteins and an increase in muscle fiber CSA, which in turn leads to an increase in the overall CSA of the muscle, thus enabling more force to be produced. Resistance exercise, i.e. overloading the muscle, has been shown to increase MPS (Chesley et al., 1992; Phillips et al., 1997), and chronic resistance exercise, i.e. RT performed over many weeks, is a potent stimulus for skeletal muscle hypertrophy and strength gains (Erskine et al., 2010b; Jones et al., 1987; Narici et al., 1996). However, exactly how overloading the muscle leads to a positive NPB and therefore an increase in muscle size has yet to be fully elucidated. It is thought that the process necessary for inducing muscle hypertrophy involves a myriad of molecules

within the muscle fiber that form signaling cascades, eventually culminating in increased MPS and/or decreased MPD. Here we will discuss how insulin-like growth factor-I (IGF-I), mechanosensors, and amino acids might activate these specific signaling pathways that lead to MPS and ultimately to muscle growth, or hypertrophy.

#### *The role of IGF-I in muscle growth*

IGF-I is produced by the liver and skeletal muscle and thus acts on muscle fibers in an endocrine and autocrine/paracrine manner (Goldspink, 1999; Stewart, Rotwein, 1996). This growth factor appears to play an integral role in activating a specific signaling pathway within the muscle fiber that stimulates MPS (Bodine et al., 2001; Rommel et al., 2001). The local production and release of IGF-I during muscle contraction (DeVol, Rotwein, Sadow, Novakofski, Bechtel, 1990) activates this signaling cascade by binding to its receptor, located in the sarcolemma. This causes autophosphorylation of the insulin receptor substrate (IRS1) and subsequent phosphorylation of down-stream molecules within this signaling pathway, which includes phosphatidylinositol-3 kinase (PI3K), protein kinase-B (PKB or Akt), the mammalian target of rapamycin complex 1 (mTORC1), 70-kDa ribosomal S6 protein kinase (p70<sup>S6K</sup>), and eukaryotic initiation factor 4E binding protein (4E-BP) (Fig. 1). In fact, p70<sup>S6K</sup> activation is related to gains in skeletal muscle mass following RT, both in rats (Baar, Esser, 1999) and humans (Terzis et al., 2008), with the increase occurring mainly in type II fibers (Koopman, Zorenc, Gransier, Cameron-Smith, van Loon, 2006). Together, these studies implicate mTORC1 and p70<sup>S6K</sup> as principal downstream mediators of IGF-I stimulation of skeletal muscle growth.

[FIGURE 1 NEAR HERE]



There is evidence that IGF-I produced in skeletal muscle is more important for developmental and exercise-induced muscle growth than IGF-I produced by the liver. This is indicated by the greater muscle mass in transgenic mice over-expressing IGF-I in skeletal muscle compared to wild-type mice (Coleman et al., 1995; Musaro et al., 2001) despite normal serum IGF-I levels (Coleman et al., 1995). Furthermore, low systemic IGF-I levels in liver-specific IGF-I knockout mice does not affect muscle size (Ohlsson et al., 2009; Yakar et al., 1999). Also in young adult men, elevated levels of circulating IGF-I do not influence MPS following an acute bout of resistance exercise (West et al., 2009) or muscle hypertrophy in response to RT (West et al., 2010). Although in rat skeletal muscle, local IGF-I gene expression increases proportionately to the progressive increase in external load (DeVol et al., 1990), it is equivocal whether this occurs in human muscle (Bamman et al., 2001; Bickel et al., 2005; Bickel, Slade, Haddad, Adams, Dudley, 2003; Hameed, Orrell, Cobbold, Goldspink, Harridge, 2003; Petrella, Kim, Cross, Kosek, Bamman, 2006; Psilander, Damsgaard, Pilegaard, 2003). Some of this controversy might be explained by the elevated expression of two isoforms of the *Igf1* gene in animal skeletal muscle in response to mechanical stimulation (McKoy et al., 1999; Yang, Alnaqeeb, Simpson, Goldspink, 1996). Thus, at least two IGF-I isoforms exist: (i) IGF-IEa, which is similar to the hepatic endocrine isoform, and (ii) the less abundant IGF-IEb (in rats) or IGF-IEc (in humans), otherwise known as mechanical growth factor (MGF). However, it is not always clear which IGF-I isoform has been measured in the muscle (Bamman et al., 2001). Furthermore, the age of the participants also influences the findings, with MGF increasing in young but not old people following an exercise bout. Interestingly, IGF-IEa does not appear to change in young or older people

following resistance exercise (Hameed et al., 2003), despite its apparent hypertrophic effect (Musaro et al., 2001).

Skeletal muscle-derived IGF-I does not appear to be the only regulator of adult muscle mass and function, as unloading induces skeletal muscle atrophy in mice whose muscles over-express IGF-I (Criswell et al., 1998), and overload induces hypertrophy even in transgenic mice, which express a dominant negative IGF-I receptor in skeletal muscle (Spangenburg, Le Roith, Ward, Bodine, 2008). Also in older people, enhanced muscle strength can be attained following RT without a significant change in muscle IGF-I gene expression (Taaffe, Jin, Vu, Hoffman, Marcus, 1996). Thus, it appears that for the development of hypertrophy in adult muscles, loading is more important than alterations in local and systemic IGF-I levels. This fits the notion that activation of mTORC1 and p70<sup>S6K</sup> can also occur independently of PI3K activation following muscle overload (Hornberger, Sukhija, Wang, Chien, 2007).

#### *The role of mechanosensors in muscle growth*

The process that couples the mechanical forces during a muscle contraction with cell signaling and ultimately protein synthesis is called mechanotransduction. It has been shown in rats that passive stretch induces an increase in the expression of myogenic regulatory factors (Kamikawa, Ikeda, Harada, Ohwatashi, Yoshida, 2013) that may well underlie the muscle fiber atrophy seen after passive stretching (Coutinho, DeLuca, Salvini, Vidal, 2006). These responses are probably at least partly mediated by stretch-activated channels (SACs), which are calcium (Ca<sup>2+</sup>) and sodium permeable channels that increase their open probability (the fraction of time spent in

the open state) in response to mechanical loading of the sarcolemma (Franco, Lansman, 1990a; Franco, Lansman, 1990b; Guharay, Sachs, 1984). It has been proposed that SACs function as mechanosensors by allowing an influx of  $\text{Ca}^{2+}$  into the muscle fiber (Yeung et al., 2005) following mechanical changes in the sarcolemma, which activate mTORC1 (Gulati et al., 2008), leading to an increase in MPS (Kameyama, Etlinger, 1979). Correspondingly, inhibition of SACs by streptomycin reduces skeletal muscle hypertrophy in response to mechanical overload (Butterfield, Best, 2009; Spangenburg, McBride, 2006) via attenuation of mTORC1 and p70<sup>S6K</sup> activation (Spangenburg et al., 2006).

Other mechanosensors might exist in the form of costameres, intra-sarcolemmal protein complexes that are circumferentially aligned along the length of the muscle fiber (Pardo, Siliciano, Craig, 1983). Costameres mechanically link peripheral myofibrils via the Z-disks to the sarcolemma (Fig. 2), thus maintaining the integrity of the muscle fiber during contraction and relaxation (Pardo et al., 1983). An individual costamere contains many proteins arranged in a complex structure (Ervasti, 2003; Patel, Lieber, 1997), which comprises two different laminin receptors, a dystrophin/glycoprotein complex and an integrin-associated complex, which are localised in the sarcolemma and bound to intra and extra-cellular structural proteins (Fig. 2). Thus, the force-producing contractile material is connected to the basal membrane and ultimately to adjacent muscle fibers (Morris, Fulton, 1994; Patel et al., 1997; Rybakova, Patel, Ervasti, 2000).

[FIGURE 2 NEAR HERE]

Costameres are receptive to mechanical, electrical and chemical stimuli (Ervasti, 2003). Indeed, mechanical tension is essential in regulating costameric protein expression, stability and organization, with talin and vinculin, for instance, being up-regulated in response to muscle contraction (Tidball, Spencer, Wehling, Laverne, 1999). Regular contractions, as experienced during RT, increase the expression of costameric proteins, such as desmin (Woolstenhulme, Conlee, Drummond, Stites, Parcell, 2006),  $\alpha$ -1-syntrophin and dystrophin (Kosek, Bamman, 2008) in humans, while focal adhesion kinase (FAK) and paxillin activity are increased in stretch-induced hypertrophied avian skeletal muscle (Fluck, Carson, Gordon, Ziemiecki, Booth, 1999). The forces exerted on both the intracellular contractile proteins and the basal membrane during periods of loading are required to cause binding of basal membrane laminin to the receptors on the  $\alpha$  and  $\beta$  integrins and on the dystrophin/glycoprotein complex (Fluck, Ziemiecki, Billeter, Muntener, 2002). Interaction between integrins and the extra-cellular matrix causes rapid phosphorylation of FAK (Cary, Guan, 1999), which subsequently activates p70<sup>S6K</sup> independently of Akt (Durieux et al., 2009; Klossner, Durieux, Freyssenet, Flueck, 2009). This probably occurs via the phosphorylation and, thus, inactivation of tuberous sclerosis complex 2 (Gan, Yoo, Guan, 2006; Malik, Parsons, 1996), thus activating mTORC1 as shown in Fig. 1.

#### *The role of amino acids in muscle growth*

Both resistance exercise (Biolo, Maggi, Williams, Tipton, Wolfe, 1995; Phillips et al., 1997) and amino acid/protein ingestion (Tang, Moore, Kujbida, Tarnopolsky, Phillips, 2009; Yang et al., 2012b) stimulate MPS independently, while a combination of the two augments MPS even further (Biolo, Tipton, Klein, Wolfe, 1997; Tipton,

Ferrando, Phillips, Doyle, Wolfe, 1999). Both stimuli cause an increase in mTORC1 activation (Apro, Blomstrand, 2010; Moore, Atherton, Rennie, Tarnopolsky, Phillips, 2011) but it is unclear whether they stimulate MPS via different signaling pathways, or whether the combination of the two stimulates the same pathway more than either stimulant on its own. It is thought that amino acids cause Rag GTPases to interact with raptor (a regulatory protein associated with mTORC1), leading to the translocation of mTORC1 to the lysosomal membrane, where Rheb (a Ras GTPase) activates mTORC1 (Kim, Guan, 2009; Sancak et al., 2010; Sancak et al., 2008), as shown in Fig. 1. Of the essential amino acids (EAAs), the branched-chain amino acids (BCAAs: isoleucine, leucine, and valine), and particularly leucine, are the most potent stimulators of the mTORC1 signaling pathway (Anthony et al., 2000). Leucine supplementation stimulates muscle protein accretion in cultured cells (Haegens, Schols, van Essen, van Loon, Langen, 2012) and can also reduce MPD in healthy men (Nair, Schwartz, Welle, 1992), and it is possible that the action of leucine occurs via its metabolite,  $\beta$ -hydroxy- $\beta$ -methylbutyrate (HMB) (Aversa et al., 2011; Pimentel et al., 2011).

The timing of amino acid ingestion appears crucial for an optimal anabolic response to a single bout of resistance exercise: ingesting amino acids immediately before an exercise bout promotes a greater increase in MPS compared to ingestion immediately after the bout (Tipton et al., 2001). This effect was attributed to an increased blood flow during exercise, and therefore an increased delivery of amino acids to the active muscle when they were ingested prior to exercise (Tipton et al., 2001). As well as the timing, the amount of protein ingested is integral in producing an optimal anabolic environment following resistance exercise (Moore et al., 2009; Witard et al., 2014;

Yang et al., 2012a). For example, the MPS dose response to ingested protein after a single bout of resistance exercise in healthy young men is saturated at 20 g protein, and any additional ingested protein is simply oxidized (Moore et al., 2009; Witard et al., 2014). This suggests that if the rate of protein ingestion after resistance exercise exceeds the rate at which it can be incorporated into the muscle, the excess protein is not used for MPS. This dose-response relationship seems to be altered with age, as in older men increased rates of MPS were found when participants ingested 40 g protein following a resistance exercise bout (Yang et al., 2012a). Therefore, older muscle appears to be less sensitive to amino acids, which has been termed ‘anabolic resistance’, something that may be attributable to impaired ribosome genesis in older muscle (Chaillou, 2017). Finally, the type and quality of the ingested protein appears to be important when it comes to MPS (Tang et al., 2009; Yang et al., 2012b). Following a single bout of resistance exercise and the ingestion of whey, soy or casein, each containing 10 g EAA, larger increases in blood EAA, BCAA, and leucine concentrations were found following the ingestion of whey compared to either soy or casein (Tang et al., 2009), suggesting a greater availability of these amino acids for protein synthesis following whey protein ingestion. This may be a reflection of the different rate of protein digestion and absorption of amino acids between the protein types (Boirie et al., 1997; Dangin et al., 2001; Dangin et al., 2003) and explain why MPS was greater following ingestion of whey compared to casein, both at rest and after exercise (Tang et al., 2009). In older muscle, the rate of MPS appears to be greater with whey than soy protein ingestion following resistance exercise (Yang et al., 2012b), which could be due to the ~28% greater leucine content in whey versus soy protein (Drummond, Rasmussen, 2008) as well as differences in digestion and absorption rate.

There is therefore striking evidence to support the acute effects of amino acid ingestion and resistance exercise on MPS via their independent and complementary effects on mTORC1 activation. It is also well known that repeated bouts of resistance exercise over a prolonged period of time, i.e. a RT program, leads to gains in both muscle size and strength (Erskine et al., 2010b; Jones et al., 1987; Narici et al., 1996). Therefore, the amplification of the anabolic environment within the muscle seen with the combination of both amino acid/protein ingestion and resistance exercise (Biolo et al., 1997; Tipton et al., 1999) suggests that RT with protein supplementation should confer greater gains in skeletal muscle size and strength than RT alone. However, the evidence for protein supplementation enhancing the increases in muscle size and strength following longer term RT programs in young (Erskine, Fletcher, Hanson, Folland, 2012; Hartman et al., 2007) and older (Candow et al., 2008; Verdijk et al., 2009b) individuals is equivocal. The controversy surrounding the longer-term RT studies could be due to methodological differences/limitations between studies. For example, considerable inter-individual variability exists in the response to RT (Erskine, Jones, Williams, Stewart, Degens, 2010a; Hubal et al., 2005) and yet many studies have used small sample sizes (Godard, Williamson, Trappe, 2002; Hulmi et al., 2009; Willoughby, Stout, Wilborn, 2007) that may have limited the statistical power required to detect an influence of protein supplementation. Different measures of muscle hypertrophy may also compound this discrepancy. For example, some studies have determined muscle thickness using ultrasonography (Candow et al., 2008; Vieillevoys, Poortmans, Duchateau, Carpentier, 2010) or whole body fat-free mass assessed via dual-energy X-ray absorptiometry (Hartman et al., 2007), while others have used magnetic resonance imaging to provide a more precise assessment of

muscle size, but still found no effect of protein supplementation on muscle hypertrophy following RT (Coburn et al., 2006; Erskine et al., 2012; Holm et al., 2008; Hulmi et al., 2009). There are, however, circumstances where protein supplementation may have a beneficial effect on muscle hypertrophy and strength gains. For example, whole body RT (incorporating multiple muscle groups rather than an individual muscle) could create a requirement for an increase in exogenous protein (due to a greater absolute MPD) that might not be satisfied by habitual protein intake alone. This might be particularly beneficial in the early phase of a RT program when MPS and MPD are likely to be higher than towards the end (Hartman, Moore, Phillips, 2006; Phillips, Tipton, Ferrando, Wolfe, 1999). In addition, older individuals need to ingest at least twice as much protein (40 g) to maximally stimulate MPS (Moore et al., 2015; Yang et al., 2012a) compared to the 20 g dose in younger people (Moore et al., 2009; Witard et al., 2014), which may reflect an ‘anabolic resistance’ in old age. Therefore, previous studies that have not shown a beneficial effect of protein supplementation on muscle size and strength gains in older people may have been administering suboptimal amounts and types of protein per RT session. In frail elderly individuals, whose protein requirements are probably higher than in old, healthy people, more recent evidence supports the combination of 60 g/day milk protein supplementation and resistance exercise (twice weekly for six months) in increasing total leg lean mass composition over resistance training alone (Tieland et al., 2012).

## **MUSCLE ATROPHY**

Skeletal muscle atrophy is known to occur in response to disuse and numerous chronic conditions, such as cancer, AIDS, and senile sarcopenia (the age-related loss of muscle mass). Here we will focus on the mechanisms underlying sarcopenia, which



is the major cause of muscle weakness in older individuals (Evans, 1995). Although the causes of sarcopenia are not fully understood, disuse, chronic systemic inflammation and neuropathic changes leading to motoneuron death are thought to play an integral role (Degens, 2010). Motoneuron death results in denervation of muscle fibers, and ultimately the loss of muscle fibers (hypoplasia). Selective atrophy of type II fibers (Lexell, Taylor, Sjostrom, 1988) and a decrease in the proportion of type II fibers (Jakobsson, Borg, Edstrom, Grimby, 1988; Larsson, 1983; Larsson, Sjodin, Karlsson, 1978) are thought to be caused by denervation accompanied by reinnervation of these fibers by axonal sprouting from adjacent slow-twitch motor units (Brooks, Faulkner, 1994; Faulkner, Larkin, Claflin, Brooks, 2007).

#### *Chronic low-grade inflammation and sarcopenia*

Physiological aging is associated with chronic low-grade inflammation, a condition that has been termed ‘inflammaging’ (Franceschi et al., 2000). Inflammaging is characterized by elevated serum levels of pro-inflammatory cytokines such as interleukin 1 (IL-1), IL-6 and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), as well as acute phase proteins such as C-reactive protein, or CRP (Bartlett et al., 2012; Erskine et al., 2017; Franceschi et al., 2000), and increased circulating levels are associated with lower muscle mass and weakness in old age (Erskine et al., 2017; Visser et al., 2002). Furthermore, the levels of cytokines that counteract the inflammatory state, such as IL-10, are reduced with age (Bartlett et al., 2012; Lio et al., 2002). The pro-inflammatory cytokines, IL-1, IL-6 and TNF- $\alpha$  are produced by both skeletal muscle fibers and adipose cells, and are therefore also members of the adipokine family. As we age, we accumulate more adipose tissue, which is deposited in the subcutaneous, visceral and intramuscular regions, and it is particularly the visceral fat that appears to

contribute to the inflammatory environment (Pedersen, 2009).

TNF- $\alpha$  induces the production of reactive oxygen species (ROS), altering vascular permeability, which leads to leukocyte infiltration of the muscle fiber (Evans et al., 1991) and further ROS generation by the leucocytes. This release of ROS also activates NF- $\kappa$ B via degradation of I- $\kappa$ B (Fig. 1), which results in the increased expression of key enzymes of the ubiquitin-proteasome MPD system (Li, Schwartz, Waddell, Holloway, Reid, 1998). In addition, TNF- $\alpha$  interferes with satellite cell differentiation and therefore muscle growth and regeneration in old age by reducing the expression of myogenic regulatory factors (MRFs) (Degens, 2010). The MRFs are a family of muscle-specific transcription factors (MyoD, myogenin, MRF4 and myf-5) that regulate the transition from proliferation to differentiation of the satellite cell (Langen et al., 2004; Szalay, Razga, Duda, 1997). The TNF- $\alpha$ -induced activation of NF- $\kappa$ B results in a loss of MyoD mRNA (Guttridge, Mayo, Madrid, Wang, Baldwin, 2000) and, via activation of the ubiquitin-proteasome pathway (UPP) (Reid, Li, 2001; Saini, Al-Shanti, Faulkner, Stewart, 2008), breakdown of MyoD and myogenin. Thus, part of the attenuated hypertrophic response in elderly compared to younger muscle (Welle, Totterman, Thornton, 1996) could be due to a decrease in MRFs, as seen in overload-induced hypertrophy in older rats (Alway, Degens, Krishnamurthy, Smith, 2002a). TNF- $\alpha$  also stimulates the release of proteolytic enzymes, such as lysozymes (e.g. cathepsin-B) from neutrophils (Farges et al., 2002), which are thought to contribute to the MPD process (Friden, Kjørell, Thornell, 1984; Kaspersek, Snider, 1985), but the main action of the pro-inflammatory cytokines in muscle atrophy is thought to occur via the UPP.

It has been suggested that the UPP cannot breakdown intact sarcomeres, so additional mechanisms are proposed to be involved (Solomon, Baracos, Sarraf, Goldberg, 1998). For example, the activation of caspase-3 is thought to lead to cleavage of the myofilaments, actin and myosin, which are then degraded by the UPP (Du et al., 2004; Lee et al., 2004; Ottenheijm et al., 2006). The UPP involves numerous enzymes, or ligases, that regulate the ubiquitination (the coupling of ubiquitin to protein substrates), so that the ‘tagged’ protein fragments can be identified by the proteasome for the final step of MPD (DeMartino, Ordway, 1998). These ubiquitin ligases may also degrade MyoD and inhibit subsequent satellite cell activation and differentiation (see above), thus exacerbating the effects of MPD on muscle size by impairing satellite cell associated muscle growth. Expression of two genes that encode the E3 ubiquitin ligases, muscle-specific atrophy F box (MAFbx, also known as Atrogin-1) and muscle RING Finger 1 (MuRF1), has been shown to increase during different types of muscle atrophy (Gomes, Lecker, Jagoe, Navon, Goldberg, 2001; Lecker et al., 2004). The structure and function of the UPP will be discussed in more detail, below, with regard to muscle damage and repair following exercise.

#### *The role of myostatin in muscle atrophy*

Myostatin, otherwise known as growth differentiation factor-8 (GDF-8), is part of the transforming growth factor  $\beta$  superfamily and is produced in skeletal muscle. The role of myostatin as a negative regulator of muscle mass has been demonstrated by knocking out the *gdf-8* gene in mice, which leads to a 2-3 fold increase in skeletal muscle mass (McPherron, Lawler, Lee, 1997). Conversely, administering myostatin to wild-type mice induces substantial muscle wasting (Zimmers et al., 2002). Further examples of myostatin’s regulatory effect can be seen in bovine (McPherron, Lee,

1997) and human (Schuelke et al., 2004) cases, where mutation of the *gdf*-8 gene leads to a reduction in myostatin production and considerably enlarged skeletal muscles.

Once bound to the activin IIB receptor (ActRIIB), a signaling cascade is activated that leads to MPD. Key signaling proteins in this pathway include SMAD 2 and 3 (Sartori et al., 2009), which form a complex with SMAD 4 that then translocates to the nucleus where it targets genes encoding MRFs (Rodino-Klapac et al., 2009), and inhibits differentiation via the reduction of MyoD expression (Langley et al., 2002) (Fig. 1). In addition, myostatin reduces Akt/ mTORC1/p70<sup>S6K</sup> signaling (Amirouche et al., 2009; Trendelenburg et al., 2009) (Fig. 1) and is associated with smaller myotube size (Trendelenburg et al., 2009). Accordingly, the inhibition of myostatin in mature mice leads to increased activation of p70<sup>S6K</sup>, ribosomal protein S6 and skeletal muscle MPS (Welle, Burgess, Mehta, 2009). Myostatin appears to not only inhibit satellite cell differentiation and MPS, but also to induce the expression of atrogenes (genes associated with muscle atrophy) via activation of the p38 mitogen-activated protein (MAP) kinase, Erk1/2, Wnt and c-Jun N-terminal kinase (JNK) signaling pathways (Huang et al., 2007; Philip, Lu, Gao, 2005; Yang et al., 2006) (Fig. 1). This is in accord with the observation that myostatin induces cachexia by activating the UPP, i.e. phosphorylating the ubiquitin E3 ligases MAFbx and MuRF1, via FOXO1 activation rather than via the NF- $\kappa$ B pathway (McFarlane et al., 2006). However, myostatin-induced atrophy persists despite inhibiting the expression of the two E3 ligases (Trendelenburg et al., 2009). Therefore, it is likely that myostatin negatively regulates muscle growth via multiple pathways (Fig. 1). A lower expression of myostatin may therefore help to maintain muscle mass at old age, a situation reflected

by the attenuated loss of muscle mass and regenerative capacity in old myostatin-null mice compared to age-matched wild-type mice (Siriatt et al., 2006).

### *Combating sarcopenia*

RT has been shown to increase muscle size and strength in old (Reeves, Narici, Maganaris, 2004), very old (Harridge, Kryger, Stensgaard, 1999) and frail (Fiatarone et al., 1994) individuals. This beneficial effect of RT is attributable to an increase in MPS in the atrophied muscle (Kimball, O'Malley, Anthony, Crozier, Jefferson, 2004) and a reduction in MPD as a result of a reduced MAFbx and MuRF-1 gene expression (Jones et al., 2004; Mascher et al., 2008). A reduction in atrogene expression can be realized by the ability of phosphorylated Akt to block FoxO1, which would suppress the transcription of MuRF1 and MAFbx (Sandri et al., 2004), as shown in Fig. 1. In addition to the Akt/FoxO-1 pathway, mTORC1 also blocks MuRF1 and MAFbx transcription (Sandri et al., 2004). Therefore, while a degree of MPD is required for muscle remodeling, RT appears to reverse atrophy via the inhibiting effect of Akt/mTORC1 on MPD and the positive effect of mTORC1 activation on MPS (Apro et al., 2010; Moore et al., 2011), thus resulting in net protein synthesis (albeit to a lesser extent in elderly compared to younger muscle).

The apparent 'anabolic resistance' to RT in older compared to young muscle (Kimball et al., 2004; Welle et al., 1996) may not be due to an age-related reduction in the mechanosensitivity of the mTORC1 signaling pathway (Hornberger, Mateja, Chin, Andrews, Esser, 2005), although others do see a reduction in the translational signaling during overload (Thomson, Gordon, 2006). It could therefore be that the

rates of transcription and translation are reduced during overload, which may be a consequence of impaired ribosome biogenesis in older muscle (Chaillou, 2017).

Another factor that might be considered is the proposed requirement of satellite cell recruitment for the development of hypertrophy. An impaired satellite cell recruitment would then result in impaired hypertrophy and part of the problem might be a decline in satellite cell number (Shefer, Van de Mark, Richardson, Yablonka-Reuveni, 2006), particularly in type II muscle fibers of older people (Verdijk et al., 2007). Yet, paradoxically, older muscle appears to have an increased regenerative drive and protein synthesis that is more pronounced the more severe the sarcopenia. For instance, muscle mass is lower despite higher p70<sup>S6K</sup> activation and MPS in old compared to young adult rats (Kimball et al., 2004). IGF-I appears to play a key role in the activation and proliferation of satellite cells (Scime, Rudnicki, 2006), while differentiation is regulated by MRFs (Langen et al., 2004; Szalay et al., 1997). However, despite an increased regenerative drive as reflected by elevated IGF-I expression (Edstrom, Ulfhake, 2005) and MRF mRNA expression (Alway, Degens, Lowe, Krishnamurthy, 2002b) in old rat muscle, MRF protein levels are reduced (Alway et al., 2002b). This reduction might be caused by a concomitant increase in Id protein expression (Alway et al., 2002b), which inhibits MRF expression and DNA binding capacity. The result is that during an hypertrophic stimulus, satellite cell activation and proliferation can occur in older rat skeletal muscle but with limited differentiation (Edstrom et al., 2005). In elderly human skeletal muscle, however, the capacity for satellite cells to proliferate and differentiate in response to RT does not appear to be diminished (Mackey et al., 2007; Verdijk et al., 2009a). It should be noted, however, that the relative age in the human studies was less than that in the rat

studies and it may be that beyond a given age in humans, the differentiation of satellite cells may also be diminished, particularly when associated with chronic low-grade systemic inflammation.

Although satellite cells are generally considered to play an important role in muscle hypertrophy, the conditional ablation of satellite cells by tamoxifen in Pax7-DTA mice did not attenuate the development of 100% hypertrophy induced by overload (McCarthy et al., 2011). It may well be that the microcirculation is crucial for the development of hypertrophy as it has been found that in genetically modified mice with muscle hypertrophy (due to myostatin knock out) and high-oxidative fibers (overexpression of oestrogen-related receptor gamma) the regenerative capacity was normal despite a lower satellite cell content, but higher capillary density (Omairi et al., 2016). Also in aged mice, the blunted hypertrophic response was associated not only associated with a lower satellite cell content (Ballak et al., 2015), but also with impaired angiogenesis (Ballak et al., 2016). These data suggest that impaired angiogenesis and/or reductions in the capillarization, that would result in an impaired delivery of substrates, of the muscle may underlie the impaired regenerative capacity and anabolic resistance in old age

Extra stimulation of the mTORC1 pathway may overcome the anabolic blunting. As discussed above, older people need to ingest more protein than younger individuals to stimulate maximal MPS (Moore et al., 2015; Moore et al., 2009; Volpi, Mittendorfer, Rasmussen, Wolfe, 2000; Yang et al., 2012a). The greater activation of the mTORC1 pathway when combining RT with protein/amino acid ingestion may inhibit MPD and augment MPS, thereby improving the hypertrophic response. The observation that

BCAA administration attenuates the loss of body mass in mice bearing a cachexia-inducing tumor (Eley, Russell, Tisdale, 2007) is promising and suggests that it may also enhance the hypertrophic response in this condition. Furthermore, HMB has been shown to attenuate the reduction in MPS in rodents following the administration of a cachectic stimulant (Aversa et al., 2011; Eley, Russell, Baxter, Mukerji, Tisdale, 2007).

In addition to RT and amino acid supplementation, various pharmaceutical therapies have been proposed to combat sarcopenia. Supplementation of the anabolic steroid, testosterone, augments muscle mass in older men, healthy hypogonadal men, older men with low testosterone levels, and men with chronic illness and low testosterone levels (Bhasin et al., 2006). It is thought that testosterone can reverse sarcopenia by suppressing skeletal muscle myostatin expression, while simultaneously stimulating the Akt pathway (Kovacheva, Hikim, Shen, Sinha, Sinha-Hikim, 2010) to increase MPS and decrease MPD. Furthermore, administration of a myostatin antagonist has led to satellite cell activation, increased MyoD protein expression, and greater muscle regeneration after injury in old murine skeletal muscle (Siriatt et al., 2007).

## **MUSCLE DAMAGE AND REPAIR**

In normal skeletal muscle, cytoskeletal proteins act as a framework that keeps the myofibrils aligned in a lateral position by connecting the Z-disks to one another and to the sarcolemma (Friden et al., 1984; Friden et al., 1983). Following eccentric exercise, Z-disk streaming (disturbance of Z-disk configuration) and misalignment of the myofibrils is a common characteristic (Friden et al., 1984). Eccentric contractions are defined as contractions where muscles lengthen as they exert force and generally



result in more muscle damage than concentric contractions (Clarkson, Hubal, 2002). It has been suggested that this is due to fewer motor units being recruited during eccentric exercise, leading to a smaller CSA of muscle being activated than during a concentric contraction at the same load (Enoka, 1996). It has also been demonstrated that the extent of muscle damage is due to strain (the change in length) rather than the amount of force generated by the muscle (Lieber, Friden, 1993; Lieber, Friden, 1999).

Eccentric exercise not only causes alterations in the cytoskeletal structure, but also increases in the activity of proteolytic enzymes (Arthur, Booker, Belcastro, 1999; Kasperek et al., 1985; Stupka, Tarnopolsky, Yardley, Phillips, 2001). The positive correlation between the proteolytic enzyme activity and a rise in serum concentrations of muscle-specific proteins, e.g. creatine kinase (CK), post exercise (Arthur et al., 1999; Kasperek et al., 1985; Stupka et al., 2001), suggests that the degree of activation of the proteolytic machinery is related to the degree of muscle damage. Therefore, it is feasible that the activity of these proteolytic enzymes may be required for the remodeling of skeletal muscle in response to exercise, where the regulated degradation of cellular proteins (Ordway, Neufer, Chin, DeMartino, 2000) may be a pre-requisite for subsequent adaptive repair and growth.

There are three main systems that contribute to the controlled MPD following muscle damage; 1) the release of calpain, a non-lysosomal,  $\text{Ca}^{2+}$ -dependent neutral protease that mediates the dismantling of myofibrils (Belcastro, Shewchuk, Raj, 1998), 2) the inflammatory response, which includes lysosomal proteolysis (Farges et al., 2002), and 3) the ATP-dependent UPP, which coordinates the demolition of protein fragments liberated by the aforementioned degradation systems (DeMartino et al.,

1998). Recent findings suggest that myostatin is also implicated in the MPD process following damaging muscle contractions (Ochi et al., 2010).

#### *The calpain protein degradation system*

Calpain is a multidomain protein composed of two subunits, a catalytic 80-kDa subunit and a regulatory 30-kDa subunit (Suzuki, Sorimachi, Yoshizawa, Kinbara, Ishiura, 1995). In skeletal muscle, three homologous isozymes of calpain with different  $\text{Ca}^{2+}$  sensitivities have been identified (DeMartino et al., 1998):  $\mu$ -calpain (active at micromolar  $\text{Ca}^{2+}$  concentrations), m-calpain (active at millimolar  $\text{Ca}^{2+}$  concentrations), and n-calpain (requiring very high  $\text{Ca}^{2+}$  concentrations). It appears that, although the  $\mu$ - and m-calpain 80-kDa subunits are quite different, both have similar binding domains; the proteolytic site of a cysteine proteinase, the calpastatin (an endogenous inhibitor of calpain activity) binding domain, and the  $\text{Ca}^{2+}$ -binding domain (Belcastro et al., 1996). The 30-kDa subunit is extremely hydrophobic, which may help to act as an anchor to the membrane proteins (Belcastro et al., 1996). While there is evidence to suggest calpain is localized and activated at or around the sarcolemma, thus targeting the membrane-associated proteins (Belcastro et al., 1998), others have demonstrated that calpain also targets Z-disk proteins, such as desmin and  $\alpha$ -actinin (Goll, Dayton, Singh, Robson, 1991). The action of other proteolytic complexes, including lysosomal enzymes and the UPP, may have a part to play in MPD immediately after damaging eccentric muscle contractions, but as their activity does not peak until later in the muscle damage/repair process (Belcastro et al., 1998; Kasperek et al., 1985), it is more likely that calpain and/or mechanical stress is the initial effector of cytoskeletal protein breakdown.

Calpain is activated by raised intracellular  $[Ca^{2+}]$  (Belcastro et al., 1998). Initial mechanical damage to the sarcoplasmic reticulum (SR) and muscle plasma membrane caused by eccentric muscle contractions could lead to SR vacuolization and an increase in intracellular  $[Ca^{2+}]$  (Clarkson et al., 2002; Warren, Hayes, Lowe, Armstrong, 1993). The intracellular  $[Ca^{2+}]$  could rise further following an increased open probability of SACs as a consequence of increased strain on the skeletal muscle fibers during forced lengthening (Lieber et al., 1993). It is thought that the activation of calpain is pivotal in the breakdown of cytoskeletal proteins, including desmin and  $\alpha$ -actinin, rather than mechanical stress applied to the “over-stretched” sarcomeres during eccentric contractions *per se* (Belcastro et al., 1998). The activity of calpain is not only dependent on the intracellular  $[Ca^{2+}]$  but also on the concentration of its inhibitor, calpastatin, and condition of degradable substrates, i.e. the ultrastructural proteins. To become fully active, calpain undergoes autolysis into its subunits. It is likely that the influx of excess  $Ca^{2+}$  into the muscle fiber (via the SACs, SR calcium channels and sarcolemmal lesions) binds to the specific domain on the 80-kDa calpain subunit, thereby inhibiting calpastatin. Once calpain is free of calpastatin, it may begin autolysis and/or bind to its substrate (with the help of  $Ca^{2+}$ ) and begin the process of MPD (Belcastro et al., 1996). A positive relationship between calpain activity and neutrophil accumulation within skeletal muscle after exercise suggests that the calpain-degraded protein fragments act as chemoattractants, thus localizing leukocytes to the site of muscle damage (Belcastro et al., 1998; Raj, Booker, Belcastro, 1998).

### *The inflammatory response*

Exercise-induced damage to muscle fibers elicits an inflammatory response that

results in movement of fluid, plasma proteins and leukocytes to the site of injury (Clarkson et al., 2002). Leukocytes have the ability to break down intracellular proteins with the aid of lysosomal enzymes (Friden et al., 1984), but exactly how the inflammatory response regulates MPD and muscle repair following eccentric exercise is not entirely clear. However, the purpose of the post-exercise-induced inflammatory response is to promote clearance of damaged muscle tissue and prepare the muscle for repair (MacIntyre et al., 1995), a process that is sub-classified into acute and secondary inflammation.

The acute phase response in skeletal muscle begins with the ‘complement system’ when fragments from the damaged fiber(s) serve as chemoattractants, luring leukocytes to the injured area (Belcastro et al., 1998; Evans et al., 1991). As a consequence there is an accumulation of neutrophils, the histological hallmark of acute inflammation (MacIntyre et al., 1995), in and around the site of injury, which peaks around 4 hours after exercise-induced damage has occurred (Evans et al., 1991). The accumulation of neutrophils has been reported to be more significant after eccentric than concentric exercise, and is most likely related to the degree of damage incurred (Evans et al., 1991). Pro-inflammatory cytokines, such as IL-1, IL-6, TNF- $\alpha$ , and acute phase proteins, e.g. CRP, act as mediators of inflammatory reactions. TNF- $\alpha$  induces the production of ROS, altering vascular permeability, which leads to leukocyte infiltration into the muscle fiber (Evans et al., 1991). TNF- $\alpha$  also stimulates the release of cytotoxic factors from neutrophils, such as lysozymes and ROS (Friden et al., 1984; MacIntyre et al., 1995), which are responsible for at least a part of the MPD process following exercise-induced damage (Friden et al., 1984; Kasperek et al., 1985).

It may take up to seven days to see a significant infiltration of monocytes (precursors to macrophages) within the damaged muscle fiber (Evans et al., 1991), which carry out further phagocytic activity inside the muscle fiber. Furthermore, considerable increases in the quantity of lipofuscin granules (generally considered to be the indigestible residue of lysosomal degradation) in sore muscles three days after exercise suggests that lysozyme activity plays a major part in the secondary inflammatory process (Farges et al., 2002; Friden, 1984). The role of the inflammatory response in muscle regeneration is therefore thought to be the further breakdown of damaged muscle proteins via lysozymes, the engulfing of protein fragments by macrophages and the activation of the UPP by the pro-inflammatory cytokines released from the neutrophils. These cytokines simultaneously stimulate the proliferation of satellite cells, crucial for the regeneration of the damaged area (Chen, Jin, Li, 2007).

#### *The ubiquitin-proteasome pathway*

This pathway is recognized as the major non-lysosomal complex responsible for the degradation of cellular proteins. The UPP has received much attention due to its involvement in cellular processes, where protein degradation is a key regulatory or adaptive event (Attaix et al., 1998; Attaix, Combaret, Pouch, Taillandier, 2001; Ciechanover, 1994). There are two types of ubiquitin in human skeletal muscle: free and conjugated (Thompson, Scordilis, 1994). In its free state ubiquitin is a normal component of the non-stressed muscle fiber but it also forms complexes, or conjugations, with abnormal proteins and then returns to its free state (Fig. 3). The conjugation of ubiquitin with denatured proteins within the muscle fiber “tags” these

proteins for recognition by a non-lysosomal protease to be subsequently degraded in a process that requires ATP (Attaix et al., 1998). The UPP, therefore, consists of two major components that represent the system's functionally distinct parts. Ubiquitin is the element that covalently binds to the protein due to be broken down, while the 26S proteasome, a large protease complex, catalyses the degradation of the ubiquitin-tagged proteins (DeMartino et al., 1998).

[FIGURE 3 NEAR HERE]

The cellular proteins are selected for degradation by the attachment of multiple molecules of ubiquitin, or a polyubiquitin chain, which is built by repeated cycles of conjugation via the action of E1, E2, and E3 conjugating enzymes (Fig. 3). Ubiquitin is initially activated in the presence of ATP by the ubiquitin-activating enzyme, E1, which then transfers ubiquitin to E2, one of the ubiquitin-conjugating enzymes. E2 then binds the ubiquitin molecule to the protein substrate, which is selected for tagging by E3 (Attaix et al., 2001). The 26S proteasome is able to discriminate between ubiquitinated and non-ubiquitinated proteins, and rapidly degrades the polyubiquitinated proteins, deriving the energy for this process from ATP hydrolysis (Hershko, Ciechanover, 1998).

The 26S proteasome is composed of a 20S proteasome and two 19S (PA700) regulatory modules (Attaix et al., 2001; Ciechanover, 1994; DeMartino et al., 1998). The 20S proteasome is the proteolytic core, containing multiple catalytic sites. PA700 binds to each end of the proteasome cylinder and elicits ATPase activity in order to unfold and/or translocate the ubiquitinated proteins to the catalytic sites within the

20S proteasome (Fig. 3). PA700 is also thought to be responsible for disassembling the polyubiquitinated chain, a process requiring its isopeptidase activity.

The total amount of ubiquitin found in skeletal muscle is muscle fiber-type specific, with a greater abundance of ubiquitin found in type I fibers (Riley et al., 1992). Furthermore, a three to seven times higher density of conjugated ubiquitin was found at the Z-discs than anywhere else in the muscle fiber, which suggests that, like calpain, ubiquitin targets the cytoskeletal proteins of muscle fibers. One main difference between the two systems, however, is that calpain is activated a lot earlier than the ubiquitin-proteasome pathway (Feasson et al., 2002; Stupka et al., 2001). Furthermore, the action of the UPP may be prolonged post-exercise in order to increase the intracellular concentration of amino acids (Tipton, Wolfe, 1998), which would stimulate MPS via mTORC1 activation.

#### *Repair following exercise-induced muscle damage*

Following the orderly demolition of damaged/cleaved muscle proteins (via the aforementioned MPD systems) in response to eccentric contractions, the damaged muscle fibers need to undergo repair. The activation, proliferation and fusion of satellite cells with damaged muscle fibers, and the subsequent differentiation into myoblasts, are crucial for this repair process (McCarthy et al., 2011; Petrella et al., 2006). In fact, it has been shown that while the hypertrophic response maybe maintained in the absence of satellite cell recruitment, recovery from damage was severely impaired under these conditions (McCarthy et al., 2011).

As previously discussed, IGF-I and MRFs are integral in the activation and differentiation of satellite cells (Langen et al., 2004; Scime et al., 2006; Szalay et al., 1997), which probably explains why skeletal muscle IGF-I and MRF expression are increased following stretch-induced damage (Bickel et al., 2005; Petrella et al., 2006; Yang, Alnaqeeb, Simpson, Goldspink, 1997; Yang, Creer, Jemiolo, Trappe, 2005). To repair the muscle, satellite cells fuse with damaged fibers and differentiate into myonuclei, but may even form new fibers in the case of complete fiber necrosis. The orderly proliferation and subsequent differentiation is crucial for optimal repair. For the initial proliferation of satellite cells the inflammatory environment is beneficial, but this inflammation must be transient to allow the cells to differentiate (Pelosi et al., 2007). Therefore, it may be that chronic low-grade systemic inflammation, e.g. during ageing, may underlie the delay in muscle regeneration (Langen et al., 2006).

## **SUMMARY**

Skeletal muscle is able to hypertrophy in response to a variety of anabolic stimuli, which include resistance exercise, amino acid ingestion, and an increase in IGF-I expression. All these stimuli are able to activate the mTORC1 signaling pathway, which stimulates MPS and inhibits MPD. When the rate of MPS exceeds MPD, there is a positive net protein balance (NPB) and an accretion of contractile material occurs, leading to muscle hypertrophy and an increase in strength. Inducing muscle hypertrophy can have beneficial effects on individuals suffering from cachectic conditions, such as cancer, AIDS, and sarcopenia, where muscle atrophy can have devastating effects on an individual's quality of life. Muscle atrophy occurs when there is a negative NPB, i.e. when the rate of MPD is greater than MPS. There are a number of stimuli that have been associated with muscle atrophy, including



chronically elevated levels of pro-inflammatory cytokines (e.g. IL-1, IL-6 and TNF- $\alpha$ ), a reduction in IGF-I and increased expression of myostatin. Furthermore, strenuous unaccustomed exercise can cause mechanical damage to the muscle, which activates MPD systems, including calpain, inflammation and the ubiquitin-proteasome protein degradation pathway. Damaged proteins within the muscle fiber are broken down, resulting in an increased intracellular amino acid concentration, which in turn activates mTORC1 and increases MPS, thus helping to repair the muscle. Elevated local IGF-I and MRF expression facilitates the repair process by activating satellite cells and enabling fusion with existing fibers. Many of the molecular signaling pathways associated with muscle hypertrophy, atrophy and repair have been identified. However, there is still much to be learned about these pathways, and understanding them may help us to prevent or reverse muscle atrophy associated with a host of muscle wasting conditions.

## REFERENCES

- Alway, S.E., Degens, H., Krishnamurthy, G., Smith, C.A. 2002a. Potential role for Id myogenic repressors in apoptosis and attenuation of hypertrophy in muscles of aged rats. *Am J Physiol Cell Physiol* 283, C66-76.
- Alway, S.E., Degens, H., Lowe, D.A., Krishnamurthy, G. 2002b. Increased myogenic repressor Id mRNA and protein levels in hindlimb muscles of aged rats. *Am J Physiol Regul Integr Comp Physiol* 282, R411-422.
- Amirouche, A., Durieux, A.C., Banzet, S., Koulmann, N., Bonnefoy, R., Mouret, C., Bigard, X., Peinnequin, A., Freyssen, D. 2009. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. *Endocrinology* 150, 286-294.
- Anthony, J.C., Yoshizawa, F., Anthony, T.G., Vary, T.C., Jefferson, L.S., Kimball, S.R. 2000. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. *J Nutr* 130, 2413-2419.
- Apro, W., Blomstrand, E. 2010. Influence of supplementation with branched-chain amino acids in combination with resistance exercise on p70S6 kinase phosphorylation in resting and exercising human skeletal muscle. *Acta Physiol (Oxf)* 200, 237-248.
- Arthur, G.D., Booker, T.S., Belcastro, A.N. 1999. Exercise promotes a subcellular redistribution of calcium-stimulated protease activity in striated muscle. *Can J Physiol Pharmacol* 77, 42-47.
- Attaix, D., Aurousseau, E., Combaret, L., Kee, A., Larbaud, D., Ralliere, C., Souweine, B., Taillandier, D., Tilignac, T. 1998. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. *Reprod Nutr Dev* 38, 153-165.
- Attaix, D., Combaret, L., Pouch, M.N., Taillandier, D. 2001. Regulation of proteolysis. *Curr Opin Clin Nutr Metab Care* 4, 45-49.
- Aversa, Z., Bonetto, A., Costelli, P., Minero, V.G., Penna, F., Baccino, F.M., Lucia, S., Rossi Fanelli, F., Muscaritoli, M. 2011. beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. *Int J Oncol* 38, 713-720.
- Baar, K., Esser, K. 1999. Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise. *Am J Physiol* 276, C120-127.
- Ballak, S.B., Buse-Pot, T., Harding, P.J., Yap, M.H., Deldicque, L., de Haan, A., Jaspers, R.T., Degens, H. 2016. Blunted angiogenesis and hypertrophy are associated with increased fatigue resistance and unchanged aerobic capacity in old overloaded mouse muscle. *Age (Dordr)* 38, 39.
- Ballak, S.B., Jaspers, R.T., Deldicque, L., Chalil, S., Peters, E.L., de Haan, A., Degens, H. 2015. Blunted hypertrophic response in old mouse muscle is associated with a lower satellite cell density and is not alleviated by resveratrol. *Exp Gerontol* 62, 23-31.

Bamman, M.M., Newcomer, B.R., Larson-Meyer, D.E., Weinsier, R.L., Hunter, G.R. 2000. Evaluation of the strength-size relationship in vivo using various muscle size indices. *Med Sci Sports Exerc* 32, 1307-1313.

Bamman, M.M., Shipp, J.R., Jiang, J., Gower, B.A., Hunter, G.R., Goodman, A., McLafferty, C.L., Jr., Urban, R.J. 2001. Mechanical load increases muscle IGF-I and androgen receptor mRNA concentrations in humans. *Am J Physiol Endocrinol Metab* 280, E383-390.

Bartlett, D.B., Firth, C.M., Phillips, A.C., Moss, P., Baylis, D., Syddall, H., Sayer, A.A., Cooper, C., Lord, J.M. 2012. The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection. *Aging Cell* 11, 912-915.

Baumert, P., Lake, M.J., Stewart, C.E., Drust, B., Erskine, R.M. 2016. Genetic variation and exercise-induced muscle damage: implications for athletic performance, injury and ageing. *Eur J Appl Physiol* 116, 1595-1625.

Belcastro, A.N., Albisser, T.A., Littlejohn, B. 1996. Role of calcium-activated neutral protease (calpain) with diet and exercise. *Can J Appl Physiol* 21, 328-346.

Belcastro, A.N., Shewchuk, L.D., Raj, D.A. 1998. Exercise-induced muscle injury: a calpain hypothesis. *Mol Cell Biochem* 179, 135-145.

Bhasin, S., Calof, O.M., Storer, T.W., Lee, M.L., Mazer, N.A., Jasuja, R., Montori, V.M., Gao, W., Dalton, J.T. 2006. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. *Nat Clin Pract Endocrinol Metab* 2, 146-159.

Bickel, C.S., Slade, J., Mahoney, E., Haddad, F., Dudley, G.A., Adams, G.R. 2005. Time course of molecular responses of human skeletal muscle to acute bouts of resistance exercise. *J Appl Physiol* 98, 482-488.

Bickel, C.S., Slade, J.M., Haddad, F., Adams, G.R., Dudley, G.A. 2003. Acute molecular responses of skeletal muscle to resistance exercise in able-bodied and spinal cord-injured subjects. *J Appl Physiol* 94, 2255-2262.

Biolo, G., Maggi, S.P., Williams, B.D., Tipton, K.D., Wolfe, R.R. 1995. Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. *Am J Physiol* 268, E514-520.

Biolo, G., Tipton, K.D., Klein, S., Wolfe, R.R. 1997. An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. *Am J Physiol* 273, E122-129.

Bodine, S.C., Stitt, T.N., Gonzalez, M., Kline, W.O., Stover, G.L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J.C., Glass, D.J., Yancopoulos, G.D. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. *Nat Cell Biol* 3, 1014-1019.

- Boirie, Y., Dangen, M., Gachon, P., Vasson, M.P., Maubois, J.L., Beaufrere, B. 1997. Slow and fast dietary proteins differently modulate postprandial protein accretion. *Proc Natl Acad Sci U S A* 94, 14930-14935.
- Brooks, S.V., Faulkner, J.A. 1994. Skeletal muscle weakness in old age: underlying mechanisms. *Med Sci Sports Exerc* 26, 432-439.
- Butterfield, T.A., Best, T.M. 2009. Stretch-activated ion channel blockade attenuates adaptations to eccentric exercise. *Med Sci Sports Exerc* 41, 351-356.
- Candow, D.G., Little, J.P., Chilibeck, P.D., Abeysekara, S., Zello, G.A., Kazachkov, M., Cornish, S.M., Yu, P.H. 2008. Low-dose creatine combined with protein during resistance training in older men. *Med Sci Sports Exerc* 40, 1645-1652.
- Cary, L.A., Guan, J.L. 1999. Focal adhesion kinase in integrin-mediated signaling. *Front Biosci* 4, D102-113.
- Chaillou, T. 2017. Impaired ribosome biogenesis could contribute to anabolic resistance to strength exercise in the elderly. *J Physiol* 595, 1447-1448.
- Chen, S.E., Jin, B., Li, Y.P. 2007. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. *Am J Physiol Cell Physiol* 292, C1660-1671.
- Chesley, A., MacDougall, J.D., Tarnopolsky, M.A., Atkinson, S.A., Smith, K. 1992. Changes in human muscle protein synthesis after resistance exercise. *J Appl Physiol* 73, 1383-1388.
- Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. *Cell* 79, 13-21.
- Clarkson, P.M., Hubal, M.J. 2002. Exercise-induced muscle damage in humans. *Am J Phys Med Rehabil* 81, S52-69.
- Clarkson, P.M., Sayers, S.P. 1999. Etiology of exercise-induced muscle damage. *Can J Appl Physiol* 24, 234-248.
- Coburn, J.W., Housh, D.J., Housh, T.J., Malek, M.H., Beck, T.W., Cramer, J.T., Johnson, G.O., Donlin, P.E. 2006. Effects of leucine and whey protein supplementation during eight weeks of unilateral resistance training. *J Strength Cond Res* 20, 284-291.
- Coleman, M.E., DeMayo, F., Yin, K.C., Lee, H.M., Geske, R., Montgomery, C., Schwartz, R.J. 1995. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. *J Biol Chem* 270, 12109-12116.
- Coutinho, E.L., DeLuca, C., Salvini, T.F., Vidal, B.C. 2006. Bouts of passive stretching after immobilization of the rat soleus muscle increase collagen macromolecular organization and muscle fiber area. *Connect Tissue Res* 47, 278-286.
- Criswell, D.S., Booth, F.W., DeMayo, F., Schwartz, R.J., Gordon, S.E., Fiorotto, M.L. 1998. Overexpression of IGF-I in skeletal muscle of transgenic mice does not prevent unloading-induced atrophy. *Am J Physiol* 275, E373-379.

Dangin, M., Boirie, Y., Garcia-Rodenas, C., Gachon, P., Fauquant, J., Callier, P., Ballevre, O., Beaufre, B. 2001. The digestion rate of protein is an independent regulating factor of postprandial protein retention. *Am J Physiol Endocrinol Metab* 280, E340-348.

Dangin, M., Guillet, C., Garcia-Rodenas, C., Gachon, P., Bouteloup-Demange, C., Reiffers-Magnani, K., Fauquant, J., Ballevre, O., Beaufre, B. 2003. The rate of protein digestion affects protein gain differently during aging in humans. *J Physiol* 549, 635-644.

Degens, H. 2010. The role of systemic inflammation in age-related muscle weakness and wasting. *Scand J Med Sci Sports* 20, 28-38.

Delhaas, T., van der Meer, S.F.T., Schaart, G., Degens, H., Drost, M.R. In Press. Steep increase in myonuclear domain size during infancy. *Anat Rec*.

DeMartino, G.N., Ordway, G.A. 1998. Ubiquitin-proteasome pathway of intracellular protein degradation: implications for muscle atrophy during unloading. *Exerc Sport Sci Rev* 26, 219-252.

DeVol, D.L., Rotwein, P., Sadow, J.L., Novakofski, J., Bechtel, P.J. 1990. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. *Am J Physiol* 259, E89-95.

Drummond, M.J., Rasmussen, B.B. 2008. Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. *Curr Opin Clin Nutr Metab Care* 11, 222-226.

Du, J., Wang, X., Miereles, C., Bailey, J.L., Debigare, R., Zheng, B., Price, S.R., Mitch, W.E. 2004. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. *J Clin Invest* 113, 115-123.

Durieux, A.C., D'Antona, G., Desplanches, D., Freyssenet, D., Klossner, S., Bottinelli, R., Fluck, M. 2009. Focal adhesion kinase is a load-dependent governor of the slow contractile and oxidative muscle phenotype. *J Physiol* 587, 3703-3717.

Ebbeling, C.B., Clarkson, P.M. 1989. Exercise-induced muscle damage and adaptation. *Sports Med* 7, 207-234.

Edstrom, E., Ulfhake, B. 2005. Sarcopenia is not due to lack of regenerative drive in senescent skeletal muscle. *Aging Cell* 4, 65-77.

Eley, H.L., Russell, S.T., Baxter, J.H., Mukerji, P., Tisdale, M.J. 2007. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. *Am J Physiol Endocrinol Metab* 293, E923-931.

Eley, H.L., Russell, S.T., Tisdale, M.J. 2007. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. *Biochem J* 407, 113-120.

Enoka, R.M. 1996. Eccentric contractions require unique activation strategies by the nervous system. *J Appl Physiol* 81, 2339-2346.

Erskine, R.M., Fletcher, G., Folland, J.P. 2014. The contribution of muscle hypertrophy to strength changes following resistance training. *Eur J Appl Physiol* 114, 1239-1249.

Erskine, R.M., Fletcher, G., Hanson, B., Folland, J.P. 2012. Whey protein does not enhance the adaptations to elbow flexor resistance training. *Med Sci Sports Exerc* 44, 1791-1800.

Erskine, R.M., Jones, D.A., Williams, A.G., Stewart, C.E., Degens, H. 2010a. Inter-individual variability in the adaptation of human muscle specific tension to progressive resistance training. *Eur J Appl Physiol* 110, 1117-1125.

Erskine, R.M., Jones, D.A., Williams, A.G., Stewart, C.E., Degens, H. 2010b. Resistance training increases in vivo quadriceps femoris muscle specific tension in young men. *Acta Physiol (Oxf)* 199, 83-89.

Erskine, R.M., Tomlinson, D.J., Morse, C.I., Winwood, K., Hampson, P., Lord, J.M., Onambele, G.L. 2017. The individual and combined effects of obesity- and ageing-induced systemic inflammation on human skeletal muscle properties. *Int J Obes (Lond)* 41, 102-111.

Ervasti, J.M. 2003. Costameres: the Achilles' heel of Herculean muscle. *J Biol Chem* 278, 13591-13594.

Evans, W.J. 1995. What is sarcopenia? *J Gerontol A Biol Sci Med Sci* 50 Spec No, 5-8.

Evans, W.J., Cannon, J.G. 1991. The metabolic effects of exercise-induced muscle damage. *Exerc Sport Sci Rev* 19, 99-125.

Farges, M.C., Balcerzak, D., Fisher, B.D., Attaix, D., Bechet, D., Ferrara, M., Baracos, V.E. 2002. Increased muscle proteolysis after local trauma mainly reflects macrophage-associated lysosomal proteolysis. *Am J Physiol Endocrinol Metab* 282, E326-335.

Faulkner, J.A., Larkin, L.M., Claflin, D.R., Brooks, S.V. 2007. Age-related changes in the structure and function of skeletal muscles. *Clin Exp Pharmacol Physiol* 34, 1091-1096.

Feasson, L., Stockholm, D., Freyssenet, D., Richard, I., Duguez, S., Beckmann, J.S., Denis, C. 2002. Molecular adaptations of neuromuscular disease-associated proteins in response to eccentric exercise in human skeletal muscle. *J Physiol* 543, 297-306.

Fiatarone, M.A., O'Neill, E.F., Ryan, N.D., Clements, K.M., Solares, G.R., Nelson, M.E., Roberts, S.B., Kehayias, J.J., Lipsitz, L.A., Evans, W.J. 1994. Exercise training and nutritional supplementation for physical frailty in very elderly people. *N Engl J Med* 330, 1769-1775.

Fluck, M., Carson, J.A., Gordon, S.E., Ziemiecki, A., Booth, F.W. 1999. Focal adhesion proteins FAK and paxillin increase in hypertrophied skeletal muscle. *Am J Physiol* 277, C152-162.

- Fluck, M., Ziemiecki, A., Billeter, R., Muntener, M. 2002. Fibre-type specific concentration of focal adhesion kinase at the sarcolemma: influence of fibre innervation and regeneration. *J Exp Biol* 205, 2337-2348.
- Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., De Benedictis, G. 2000. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 908, 244-254.
- Franco, A., Jr., Lansman, J.B. 1990a. Calcium entry through stretch-inactivated ion channels in mdx myotubes. *Nature* 344, 670-673.
- Franco, A., Jr., Lansman, J.B. 1990b. Stretch-sensitive channels in developing muscle cells from a mouse cell line. *J Physiol* 427, 361-380.
- Friden, J. 1984. Muscle soreness after exercise: implications of morphological changes. *Int J Sports Med* 5, 57-66.
- Friden, J., Kjorell, U., Thornell, L.E. 1984. Delayed muscle soreness and cytoskeletal alterations: an immunocytological study in man. *Int J Sports Med* 5, 15-18.
- Friden, J., Sjostrom, M., Ekblom, B. 1983. Myofibrillar damage following intense eccentric exercise in man. *Int J Sports Med* 4, 170-176.
- Fukunaga, T., Miyatani, M., Tachi, M., Kouzaki, M., Kawakami, Y., Kanehisa, H. 2001. Muscle volume is a major determinant of joint torque in humans. *Acta Physiol Scand* 172, 249-255.
- Gan, B., Yoo, Y., Guan, J.L. 2006. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. *J Biol Chem* 281, 37321-37329.
- Godard, M.P., Williamson, D.L., Trappe, S.W. 2002. Oral amino-acid provision does not affect muscle strength or size gains in older men. *Med Sci Sports Exerc* 34, 1126-1131.
- Goldspink, G. 1999. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. *J Anat* 194 ( Pt 3), 323-334.
- Goll, D.E., Dayton, W.R., Singh, I., Robson, R.M. 1991. Studies of the alpha-actinin/actin interaction in the Z-disk by using calpain. *J Biol Chem* 266, 8501-8510.
- Gomes, M.D., Lecker, S.H., Jagoe, R.T., Navon, A., Goldberg, A.L. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc Natl Acad Sci U S A* 98, 14440-14445.
- Guharay, F., Sachs, F. 1984. Stretch-activated single ion channel currents in tissue-cultured embryonic chick skeletal muscle. *J Physiol* 352, 685-701.
- Gulati, P., Gaspers, L.D., Dann, S.G., Joaquin, M., Nobukuni, T., Natt, F., Kozma, S.C., Thomas, A.P., Thomas, G. 2008. Amino acids activate mTOR complex 1 via Ca<sup>2+</sup>/CaM signaling to hVps34. *Cell Metab* 7, 456-465.

Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.Y., Baldwin, A.S., Jr. 2000. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science* 289, 2363-2366.

Haegens, A., Schols, A.M., van Essen, A.L., van Loon, L.J., Langen, R.C. 2012. Leucine induces myofibrillar protein accretion in cultured skeletal muscle through mTOR dependent and -independent control of myosin heavy chain mRNA levels. *Mol Nutr Food Res* 56, 741-752.

Hameed, M., Orrell, R.W., Cobbold, M., Goldspink, G., Harridge, S.D. 2003. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. *J Physiol* 547, 247-254.

Harridge, S.D., Kryger, A., Stensgaard, A. 1999. Knee extensor strength, activation, and size in very elderly people following strength training. *Muscle Nerve* 22, 831-839.

Hartman, J.W., Moore, D.R., Phillips, S.M. 2006. Resistance training reduces whole-body protein turnover and improves net protein retention in untrained young males. *Appl Physiol Nutr Metab* 31, 557-564.

Hartman, J.W., Tang, J.E., Wilkinson, S.B., Tarnopolsky, M.A., Lawrence, R.L., Fullerton, A.V., Phillips, S.M. 2007. Consumption of fat-free fluid milk after resistance exercise promotes greater lean mass accretion than does consumption of soy or carbohydrate in young, novice, male weightlifters. *Am J Clin Nutr* 86, 373-381.

Hershko, A., Ciechanover, A. 1998. The ubiquitin system. *Annu Rev Biochem* 67, 425-479.

Holm, L., Olesen, J.L., Matsumoto, K., Doi, T., Mizuno, M., Alsted, T.J., Mackey, A.L., Schwarz, P., Kjaer, M. 2008. Protein-containing nutrient supplementation following strength training enhances the effect on muscle mass, strength, and bone formation in postmenopausal women. *J Appl Physiol* 105, 274-281.

Hornberger, T.A., Mateja, R.D., Chin, E.R., Andrews, J.L., Esser, K.A. 2005. Aging does not alter the mechanosensitivity of the p38, p70S6k, and JNK2 signaling pathways in skeletal muscle. *J Appl Physiol* 98, 1562-1566.

Hornberger, T.A., Sukhija, K.B., Wang, X.R., Chien, S. 2007. mTOR is the rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k). *FEBS Lett* 581, 4562-4566.

Huang, Z., Chen, D., Zhang, K., Yu, B., Chen, X., Meng, J. 2007. Regulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cells. *Cell Signal* 19, 2286-2295.

Hubal, M.J., Gordish-Dressman, H., Thompson, P.D., Price, T.B., Hoffman, E.P., Angelopoulos, T.J., Gordon, P.M., Moyna, N.M., Pescatello, L.S., Visich, P.S., Zoeller, R.F., Seip, R.L., Clarkson, P.M. 2005. Variability in muscle size and strength gain after unilateral resistance training. *Med Sci Sports Exerc* 37, 964-972.



- Hulmi, J.J., Kovanen, V., Selanne, H., Kraemer, W.J., Hakkinen, K., Mero, A.A. 2009. Acute and long-term effects of resistance exercise with or without protein ingestion on muscle hypertrophy and gene expression. *Amino Acids* 37, 297-308.
- Jacquemin, V., Furling, D., Bigot, A., Butler-Browne, G.S., Mouly, V. 2004. IGF-1 induces human myotube hypertrophy by increasing cell recruitment. *Exp Cell Res* 299, 148-158.
- Jakobsson, F., Borg, K., Edstrom, L., Grimby, L. 1988. Use of motor units in relation to muscle fiber type and size in man. *Muscle Nerve* 11, 1211-1218.
- Jones, D.A., Rutherford, O.M. 1987. Human muscle strength training: the effects of three different regimens and the nature of the resultant changes. *J Physiol* 391, 1-11.
- Jones, D.A., Rutherford, O.M., Parker, D.F. 1989. Physiological changes in skeletal muscle as a result of strength training. *Q J Exp Physiol* 74, 233-256.
- Jones, S.W., Hill, R.J., Krasney, P.A., O'Conner, B., Peirce, N., Greenhaff, P.L. 2004. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. *Faseb J* 18, 1025-1027.
- Kameyama, T., Etlinger, J.D. 1979. Calcium-dependent regulation of protein synthesis and degradation in muscle. *Nature* 279, 344-346.
- Kamikawa, Y., Ikeda, S., Harada, K., Ohwatashi, A., Yoshida, A. 2013. Passive repetitive stretching for a short duration within a week increases myogenic regulatory factors and myosin heavy chain mRNA in rats' skeletal muscles. *ScientificWorldJournal* 2013, 493656.
- Kanehisa, H., Ikegawa, S., Fukunaga, T. 1994. Comparison of muscle cross-sectional area and strength between untrained women and men. *Eur J Appl Physiol Occup Physiol* 68, 148-154.
- Kasperek, G.J., Snider, R.D. 1985. Increased protein degradation after eccentric exercise. *Eur J Appl Physiol Occup Physiol* 54, 30-34.
- Kim, E., Guan, K.L. 2009. RAG GTPases in nutrient-mediated TOR signaling pathway. *Cell Cycle* 8, 1014-1018.
- Kimball, S.R., O'Malley, J.P., Anthony, J.C., Crozier, S.J., Jefferson, L.S. 2004. Assessment of biomarkers of protein anabolism in skeletal muscle during the life span of the rat: sarcopenia despite elevated protein synthesis. *Am J Physiol Endocrinol Metab* 287, E772-780.
- Klossner, S., Durieux, A.C., Freyssenet, D., Flueck, M. 2009. Mechano-transduction to muscle protein synthesis is modulated by FAK. *Eur J Appl Physiol* 106, 389-398.
- Koopman, R., Zorenc, A.H., Gransier, R.J., Cameron-Smith, D., van Loon, L.J. 2006. Increase in S6K1 phosphorylation in human skeletal muscle following resistance exercise occurs mainly in type II muscle fibers. *Am J Physiol Endocrinol Metab* 290, E1245-1252.

- Kosek, D.J., Bamman, M.M. 2008. Modulation of the dystrophin-associated protein complex in response to resistance training in young and older men. *J Appl Physiol* 104, 1476-1484.
- Kovacheva, E.L., Hikim, A.P., Shen, R., Sinha, I., Sinha-Hikim, I. 2010. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. *Endocrinology* 151, 628-638.
- Kumar, V., Atherton, P., Smith, K., Rennie, M.J. 2009. Human muscle protein synthesis and breakdown during and after exercise. *J Appl Physiol* 106, 2026-2039.
- Langen, R.C., Schols, A.M., Kelders, M.C., van der Velden, J.L., Wouters, E.F., Janssen-Heininger, Y.M. 2006. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. *Am J Respir Cell Mol Biol* 35, 689-696.
- Langen, R.C., Van Der Velden, J.L., Schols, A.M., Kelders, M.C., Wouters, E.F., Janssen-Heininger, Y.M. 2004. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. *Faseb J* 18, 227-237.
- Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S., Kambadur, R. 2002. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. *J Biol Chem* 277, 49831-49840.
- Larsson, L. 1983. Histochemical characteristics of human skeletal muscle during aging. *Acta Physiol Scand* 117, 469-471.
- Larsson, L., Sjodin, B., Karlsson, J. 1978. Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22--65 years. *Acta Physiol Scand* 103, 31-39.
- Lecker, S.H., Jagoe, R.T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S.R., Mitch, W.E., Goldberg, A.L. 2004. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *Faseb J* 18, 39-51.
- Lee, S.W., Dai, G., Hu, Z., Wang, X., Du, J., Mitch, W.E. 2004. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. *J Am Soc Nephrol* 15, 1537-1545.
- Lexell, J., Taylor, C.C., Sjostrom, M. 1988. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. *J Neurol Sci* 84, 275-294.
- Li, Y.P., Schwartz, R.J., Waddell, I.D., Holloway, B.R., Reid, M.B. 1998. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. *Faseb J* 12, 871-880.
- Lieber, R.L., Friden, J. 1993. Muscle damage is not a function of muscle force but active muscle strain. *J Appl Physiol* 74, 520-526.

- Lieber, R.L., Friden, J. 1999. Mechanisms of muscle injury after eccentric contraction. *J Sci Med Sport* 2, 253-265.
- Lieber, R.L., Shah, S., Friden, J. 2002. Cytoskeletal disruption after eccentric contraction-induced muscle injury. *Clin Orthop Relat Res*, S90-99.
- Lio, D., Scola, L., Crivello, A., Colonna-Romano, G., Candore, G., Bonafe, M., Cavallone, L., Franceschi, C., Caruso, C. 2002. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. *Genes Immun* 3, 30-33.
- MacIntyre, D.L., Reid, W.D., McKenzie, D.C. 1995. Delayed muscle soreness. The inflammatory response to muscle injury and its clinical implications. *Sports Med* 20, 24-40.
- Mackey, A.L., Esmarck, B., Kadi, F., Koskinen, S.O., Kongsgaard, M., Sylvestersen, A., Hansen, J.J., Larsen, G., Kjaer, M. 2007. Enhanced satellite cell proliferation with resistance training in elderly men and women. *Scand J Med Sci Sports* 17, 34-42.
- Malik, R.K., Parsons, J.T. 1996. Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway. *J Biol Chem* 271, 29785-29791.
- Mascher, H., Tannerstedt, J., Brink-Elfegoun, T., Ekblom, B., Gustafsson, T., Blomstrand, E. 2008. Repeated resistance exercise training induces different changes in mRNA expression of MAFbx and MuRF-1 in human skeletal muscle. *Am J Physiol Endocrinol Metab* 294, E43-51.
- McCarthy, J.J., Mula, J., Miyazaki, M., Erfani, R., Garrison, K., Farooqui, A.B., Srikuea, R., Lawson, B.A., Grimes, B., Keller, C., Van Zant, G., Campbell, K.S., Esser, K.A., Dupont-Versteegden, E.E., Peterson, C.A. 2011. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. *Development* 138, 3657-3666.
- McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., Smith, H., Sharma, M., Kambadur, R. 2006. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. *J Cell Physiol* 209, 501-514.
- McKoy, G., Ashley, W., Mander, J., Yang, S.Y., Williams, N., Russell, B., Goldspink, G. 1999. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. *J Physiol* 516 ( Pt 2), 583-592.
- McPherron, A.C., Lawler, A.M., Lee, S.J. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature* 387, 83-90.
- McPherron, A.C., Lee, S.J. 1997. Double muscling in cattle due to mutations in the myostatin gene. *Proc Natl Acad Sci U S A* 94, 12457-12461.
- Milacic, V., Dou, Q.P. 2009. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. *Coord Chem Rev* 253, 1649-1660.

- Moore, D.R., Atherton, P.J., Rennie, M.J., Tarnopolsky, M.A., Phillips, S.M. 2011. Resistance exercise enhances mTOR and MAPK signalling in human muscle over that seen at rest after bolus protein ingestion. *Acta Physiol (Oxf)* 201, 365-372.
- Moore, D.R., Churchward-Venne, T.A., Witard, O., Breen, L., Burd, N.A., Tipton, K.D., Phillips, S.M. 2015. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. *J Gerontol A Biol Sci Med Sci* 70, 57-62.
- Moore, D.R., Robinson, M.J., Fry, J.L., Tang, J.E., Glover, E.I., Wilkinson, S.B., Prior, T., Tarnopolsky, M.A., Phillips, S.M. 2009. Ingested protein dose response of muscle and albumin protein synthesis after resistance exercise in young men. *Am J Clin Nutr* 89, 161-168.
- Morris, E.J., Fulton, A.B. 1994. Rearrangement of mRNAs for costamere proteins during costamere development in cultured skeletal muscle from chicken. *J Cell Sci* 107 ( Pt 3), 377-386.
- Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E.R., Sweeney, H.L., Rosenthal, N. 2001. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. *Nat Genet* 27, 195-200.
- Nair, K.S., Schwartz, R.G., Welle, S. 1992. Leucine as a regulator of whole body and skeletal muscle protein metabolism in humans. *Am J Physiol* 263, E928-934.
- Narici, M.V., Hoppeler, H., Kayser, B., Landoni, L., Claassen, H., Gavardi, C., Conti, M., Cerretelli, P. 1996. Human quadriceps cross-sectional area, torque and neural activation during 6 months strength training. *Acta Physiol Scand* 157, 175-186.
- Ochi, E., Hirose, T., Hiranuma, K., Min, S.K., Ishii, N., Nakazato, K. 2010. Elevation of myostatin and FOXOs in prolonged muscular impairment induced by eccentric contractions in rat medial gastrocnemius muscle. *J Appl Physiol* 108, 306-313.
- Ohlsson, C., Mohan, S., Sjogren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.O., Svensson, J. 2009. The role of liver-derived insulin-like growth factor-I. *Endocr Rev* 30, 494-535.
- Omairi, S., Matsakas, A., Degens, H., Kretz, O., Hansson, K.A., Solbra, A.V., Bruusgaard, J.C., Joch, B., Sartori, R., Giallourou, N., Mitchell, R., Collins-Hooper, H., Foster, K., Pasternack, A., Ritvos, O., Sandri, M., Narkar, V., Swann, J.R., Huber, T.B., Patel, K. 2016. Enhanced exercise and regenerative capacity in a mouse model that violates size constraints of oxidative muscle fibres. *Elife* 5.
- Ordway, G.A., Neufer, P.D., Chin, E.R., DeMartino, G.N. 2000. Chronic contractile activity upregulates the proteasome system in rabbit skeletal muscle. *J Appl Physiol* 88, 1134-1141.
- Ottenheijm, C.A., Heunks, L.M., Li, Y.P., Jin, B., Minnaard, R., van Hees, H.W., Dekhuijzen, P.N. 2006. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 174, 997-1002.

Pardo, J.V., Siliciano, J.D., Craig, S.W. 1983. Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. *J Cell Biol* 97, 1081-1088.

Patel, T.J., Lieber, R.L. 1997. Force transmission in skeletal muscle: from actomyosin to external tendons. *Exerc Sport Sci Rev* 25, 321-363.

Pedersen, B.K. 2009. The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk. *J Physiol* 587, 5559-5568.

Pelosi, L., Giacinti, C., Nardis, C., Borsellino, G., Rizzuto, E., Nicoletti, C., Wannenes, F., Battistini, L., Rosenthal, N., Molinaro, M., Musaro, A. 2007. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. *Faseb J* 21, 1393-1402.

Petrella, J.K., Kim, J.-S., Cross, J.M., Kosek, D.J., Bamman, M.M. 2006. Efficacy of myonuclear addition may explain differential myofiber growth among resistance-trained young and older men and women. *Am J Physiol Endocrinol Metab* 291, E937-946.

Philip, B., Lu, Z., Gao, Y. 2005. Regulation of GDF-8 signaling by the p38 MAPK. *Cell Signal* 17, 365-375.

Phillips, S.M., Tipton, K.D., Aarsland, A., Wolf, S.E., Wolfe, R.R. 1997. Mixed muscle protein synthesis and breakdown after resistance exercise in humans. *Am J Physiol* 273, E99-107.

Phillips, S.M., Tipton, K.D., Ferrando, A.A., Wolfe, R.R. 1999. Resistance training reduces the acute exercise-induced increase in muscle protein turnover. *Am J Physiol* 276, E118-124.

Pimentel, G.D., Rosa, J.C., Lira, F.S., Zanchi, N.E., Ropelle, E.R., Oyama, L.M., Oller do Nascimento, C.M., de Mello, M.T., Tufik, S., Santos, R.V. 2011. beta-Hydroxy-beta-methylbutyrate (HMBeta) supplementation stimulates skeletal muscle hypertrophy in rats via the mTOR pathway. *Nutr Metab (Lond)* 8, 11.

Psilander, N., Damsgaard, R., Pilegaard, H. 2003. Resistance exercise alters MRF and IGF-I mRNA content in human skeletal muscle. *J Appl Physiol* 95, 1038-1044.

Raj, D.A., Booker, T.S., Belcastro, A.N. 1998. Striated muscle calcium-stimulated cysteine protease (calpain-like) activity promotes myeloperoxidase activity with exercise. *Pflugers Arch* 435, 804-809.

Reeves, N.D., Narici, M.V., Maganaris, C.N. 2004. Effect of resistance training on skeletal muscle-specific force in elderly humans. *J Appl Physiol* 96, 885-892.

Reid, M.B., Li, Y.P. 2001. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. *Respir Res* 2, 269-272.

Riley, D.A., Ellis, S., Giometti, C.S., Hoh, J.F., Ilyina-Kakueva, E.I., Oganov, V.S., Slocum, G.R., Bain, J.L., Sedlak, F.R. 1992. Muscle sarcomere lesions and thrombosis after spaceflight and suspension unloading. *J Appl Physiol* 73, 33S-43S.

Rodino-Klapac, L.R., Haidet, A.M., Kota, J., Handy, C., Kaspar, B.K., Mendell, J.R. 2009. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. *Muscle Nerve* 39, 283-296.

Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., Yancopoulos, G.D., Glass, D.J. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat Cell Biol* 3, 1009-1013.

Rybakova, I.N., Patel, J.R., Ervasti, J.M. 2000. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. *J Cell Biol* 150, 1209-1214.

Saini, A., Al-Shanti, N., Faulkner, S.H., Stewart, C.E. 2008. Pro- and anti-apoptotic roles for IGF-I in TNF-alpha-induced apoptosis: a MAP kinase mediated mechanism. *Growth Factors* 26, 239-253.

Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A.L., Nada, S., Sabatini, D.M. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* 141, 290-303.

Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., Sabatini, D.M. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* 320, 1496-1501.

Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H., Goldberg, A.L. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* 117, 399-412.

Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., Sandri, M. 2009. Smad2 and 3 transcription factors control muscle mass in adulthood. *Am J Physiol Cell Physiol* 296, C1248-1257.

Schuelke, M., Wagner, K.R., Stolz, L.E., Hubner, C., Riebel, T., Komen, W., Braun, T., Tobin, J.F., Lee, S.J. 2004. Myostatin mutation associated with gross muscle hypertrophy in a child. *N Engl J Med* 350, 2682-2688.

Scime, A., Rudnicki, M.A. 2006. Anabolic potential and regulation of the skeletal muscle satellite cell populations. *Curr Opin Clin Nutr Metab Care* 9, 214-219.

Shefer, G., Van de Mark, D.P., Richardson, J.B., Yablonka-Reuveni, Z. 2006. Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. *Dev Biol* 294, 50-66.

Siriatt, V., Platt, L., Salerno, M.S., Ling, N., Kambadur, R., Sharma, M. 2006. Prolonged absence of myostatin reduces sarcopenia. *J Cell Physiol* 209, 866-873.

Siriatt, V., Salerno, M.S., Berry, C., Nicholas, G., Bower, R., Kambadur, R., Sharma, M. 2007. Antagonism of myostatin enhances muscle regeneration during sarcopenia. *Mol Ther* 15, 1463-1470.

- Solomon, V., Baracos, V., Sarraf, P., Goldberg, A.L. 1998. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. *Proc Natl Acad Sci U S A* 95, 12602-12607.
- Spangenburg, E.E., Le Roith, D., Ward, C.W., Bodine, S.C. 2008. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. *J Physiol* 586, 283-291.
- Spangenburg, E.E., McBride, T.A. 2006. Inhibition of stretch-activated channels during eccentric muscle contraction attenuates p70S6K activation. *J Appl Physiol* 100, 129-135.
- Stewart, C.E., Rotwein, P. 1996. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. *Physiol Rev* 76, 1005-1026.
- Stupka, N., Tarnopolsky, M.A., Yardley, N.J., Phillips, S.M. 2001. Cellular adaptation to repeated eccentric exercise-induced muscle damage. *J Appl Physiol* 91, 1669-1678.
- Suzuki, K., Sorimachi, H., Yoshizawa, T., Kinbara, K., Ishiura, S. 1995. Calpain: novel family members, activation, and physiologic function. *Biol Chem Hoppe Seyler* 376, 523-529.
- Szalay, K., Razga, Z., Duda, E. 1997. TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. *Eur J Cell Biol* 74, 391-398.
- Taaffe, D.R., Jin, I.H., Vu, T.H., Hoffman, A.R., Marcus, R. 1996. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. *J Clin Endocrinol Metab* 81, 421-425.
- Tang, J.E., Moore, D.R., Kujbida, G.W., Tarnopolsky, M.A., Phillips, S.M. 2009. Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. *J Appl Physiol* 107, 987-992.
- Terzis, G., Georgiadis, G., Stratakos, G., Vogiatzis, I., Kavouras, S., Manta, P., Mascher, H., Blomstrand, E. 2008. Resistance exercise-induced increase in muscle mass correlates with p70S6 kinase phosphorylation in human subjects. *Eur J Appl Physiol* 102, 145-152.
- Thompson, H.S., Scordilis, S.P. 1994. Ubiquitin changes in human biceps muscle following exercise-induced damage. *Biochem Biophys Res Commun* 204, 1193-1198.
- Thomson, D.M., Gordon, S.E. 2006. Impaired overload-induced muscle growth is associated with diminished translational signalling in aged rat fast-twitch skeletal muscle. *J Physiol* 574, 291-305.
- Tidball, J.G., Spencer, M.J., Wehling, M., Lavergne, E. 1999. Nitric-oxide synthase is a mechanical signal transducer that modulates talin and vinculin expression. *J Biol Chem* 274, 33155-33160.

Tieland, M., Dirks, M.L., van der Zwaluw, N., Verdijk, L.B., van de Rest, O., de Groot, L.C., van Loon, L.J. 2012. Protein Supplementation Increases Muscle Mass Gain During Prolonged Resistance-Type Exercise Training in Frail Elderly People: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Am Med Dir Assoc*.

Tipton, K.D., Ferrando, A.A., Phillips, S.M., Doyle, D., Jr., Wolfe, R.R. 1999. Postexercise net protein synthesis in human muscle from orally administered amino acids. *Am J Physiol* 276, E628-634.

Tipton, K.D., Rasmussen, B.B., Miller, S.L., Wolf, S.E., Owens-Stovall, S.K., Petrini, B.E., Wolfe, R.R. 2001. Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise. *Am J Physiol Endocrinol Metab* 281, E197-206.

Tipton, K.D., Wolfe, R.R. 1998. Exercise-induced changes in protein metabolism. *Acta Physiol Scand* 162, 377-387.

Trendelenburg, A.U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., Glass, D.J. 2009. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. *Am J Physiol Cell Physiol* 296, C1258-1270.

Verdijk, L.B., Gleeson, B.G., Jonkers, R.A., Meijer, K., Savelberg, H.H., Dendale, P., van Loon, L.J. 2009a. Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men. *J Gerontol A Biol Sci Med Sci* 64, 332-339.

Verdijk, L.B., Jonkers, R.A., Gleeson, B.G., Beelen, M., Meijer, K., Savelberg, H.H., Wodzig, W.K., Dendale, P., van Loon, L.J. 2009b. Protein supplementation before and after exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. *Am J Clin Nutr* 89, 608-616.

Verdijk, L.B., Koopman, R., Schaart, G., Meijer, K., Savelberg, H.H., van Loon, L.J. 2007. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. *Am J Physiol Endocrinol Metab* 292, E151-157.

Vieillevoys, S., Poortmans, J.R., Duchateau, J., Carpentier, A. 2010. Effects of a combined essential amino acids/carbohydrate supplementation on muscle mass, architecture and maximal strength following heavy-load training. *Eur J Appl Physiol* 110, 479-488.

Visser, M., Pahor, M., Taaffe, D.R., Goodpaster, B.H., Simonsick, E.M., Newman, A.B., Nevitt, M., Harris, T.B. 2002. Relationship of interleukin-6 and tumor necrosis factor- $\alpha$  with muscle mass and muscle strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci* 57, M326-332.

Volpi, E., Mittendorfer, B., Rasmussen, B.B., Wolfe, R.R. 2000. The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly. *J Clin Endocrinol Metab* 85, 4481-4490.

Warren, G.L., Hayes, D.A., Lowe, D.A., Armstrong, R.B. 1993. Mechanical factors in the initiation of eccentric contraction-induced injury in rat soleus muscle. *J Physiol* 464, 457-475.



Welle, S., Burgess, K., Mehta, S. 2009. Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. *Am J Physiol Endocrinol Metab* 296, E567-572.

Welle, S., Totterman, S., Thornton, C. 1996. Effect of age on muscle hypertrophy induced by resistance training. *J Gerontol A Biol Sci Med Sci* 51, M270-275.

West, D.W., Burd, N.A., Tang, J.E., Moore, D.R., Staples, A.W., Holwerda, A.M., Baker, S.K., Phillips, S.M. 2010. Elevations in ostensibly anabolic hormones with resistance exercise enhance neither training-induced muscle hypertrophy nor strength of the elbow flexors. *J Appl Physiol* 108, 60-67.

West, D.W., Kujbida, G.W., Moore, D.R., Atherton, P., Burd, N.A., Padzik, J.P., De Lisio, M., Tang, J.E., Parise, G., Rennie, M.J., Baker, S.K., Phillips, S.M. 2009. Resistance exercise-induced increases in putative anabolic hormones do not enhance muscle protein synthesis or intracellular signalling in young men. *J Physiol* 587, 5239-5247.

Willoughby, D.S., Stout, J.R., Wilborn, C.D. 2007. Effects of resistance training and protein plus amino acid supplementation on muscle anabolism, mass, and strength. *Amino Acids* 32, 467-477.

Witard, O.C., Jackman, S.R., Breen, L., Smith, K., Selby, A., Tipton, K.D. 2014. Myofibrillar muscle protein synthesis rates subsequent to a meal in response to increasing doses of whey protein at rest and after resistance exercise. *Am J Clin Nutr* 99, 86-95.

Woolstenhulme, M.T., Conlee, R.K., Drummond, M.J., Stites, A.W., Parcell, A.C. 2006. Temporal response of desmin and dystrophin proteins to progressive resistance exercise in human skeletal muscle. *J Appl Physiol* 100, 1876-1882.

Yakar, S., Liu, J.L., Stannard, B., Butler, A., Accili, D., Sauer, B., LeRoith, D. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. *Proc Natl Acad Sci U S A* 96, 7324-7329.

Yang, H., Alnaqeeb, M., Simpson, H., Goldspink, G. 1997. Changes in muscle fibre type, muscle mass and IGF-I gene expression in rabbit skeletal muscle subjected to stretch. *J Anat* 190 ( Pt 4), 613-622.

Yang, S., Alnaqeeb, M., Simpson, H., Goldspink, G. 1996. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. *J Muscle Res Cell Motil* 17, 487-495.

Yang, W., Chen, Y., Zhang, Y., Wang, X., Yang, N., Zhu, D. 2006. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. *Cancer Res* 66, 1320-1326.

Yang, Y., Breen, L., Burd, N.A., Hector, A.J., Churchward-Venne, T.A., Josse, A.R., Tarnopolsky, M.A., Phillips, S.M. 2012a. Resistance exercise enhances myofibrillar protein synthesis with graded intakes of whey protein in older men. *Br J Nutr*, 1-9.

Yang, Y., Churchward-Venne, T.A., Burd, N.A., Breen, L., Tarnopolsky, M.A., Phillips, S.M. 2012b. Myofibrillar protein synthesis following ingestion of soy protein isolate at rest and after resistance exercise in elderly men. *Nutr Metab (Lond)* 9, 57.

Yang, Y., Creer, A., Jemiolo, B., Trappe, S. 2005. Time course of myogenic and metabolic gene expression in response to acute exercise in human skeletal muscle. *J Appl Physiol* 98, 1745-1752.

Yeung, E.W., Whitehead, N.P., Suchyna, T.M., Gottlieb, P.A., Sachs, F., Allen, D.G. 2005. Effects of stretch-activated channel blockers on  $[Ca^{2+}]_i$  and muscle damage in the mdx mouse. *J Physiol* 562, 367-380.

Zimmers, T.A., Davies, M.V., Koniaris, L.G., Haynes, P., Esquela, A.F., Tomkinson, K.N., McPherron, A.C., Wolfman, N.M., Lee, S.J. 2002. Induction of cachexia in mice by systemically administered myostatin. *Science* 296, 1486-1488.

## FIGURE LEGENDS

### **Figure 1. The molecular signaling pathways associated with muscle hypertrophy and atrophy.**

The binding of IGF-I to its receptor (IGF-IR) causes autophosphorylation of insulin receptor substrate (IRS1). Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that phosphorylates phosphatidylinositol (4,5)-bisphosphate, producing phosphatidylinositol (3,4,5)-trisphosphate, which is a membrane-binding site for phosphoinositide-dependent protein kinase (PDK1). Upon translocation to the sarcolemma, AKT (or protein kinase B, PKB) is phosphorylated by PDK1. Once activated, AKT phosphorylates mammalian target of rapamycin complex 1 (mTORC1) directly and by phosphorylating and inactivating the tuberous sclerosis complexes 1 and 2 (TSC1/2), which otherwise inhibit mTORC1 activation. Following resistance exercise, an influx of calcium ions ( $\text{Ca}^{2+}$ ) via stretch-activated channels (SACs) and the activation of FAK in the costamere can inactivate TSC1/2, thus activating mTORC1. Amino acids entering the muscle fiber cause RagGTPase-dependent translocation of mTORC1 to the lysosome, where it is activated by ras homologous protein enriched in brain (Rheb). mTORC1 subsequently activates 70KDa ribosomal S6 protein kinase ( $\text{p70}^{\text{S6K}}$ ), and inhibits 4E-BP (also known as PHAS-1), which is a negative regulator of the eukaryotic translation initiation factor 4E (eIF-4E). Phosphorylated AKT also inhibits glycogen-synthase kinase  $3\beta$  (GSK3 $\beta$ ), a substrate of AKT that blocks protein translation initiated by the eIF-2B protein. All of these actions lead to increased protein synthesis. However, protein degradation can be induced by pro-inflammatory cytokines, such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6 (IL-6), which activate NF- $\kappa$ B via degradation of I- $\kappa$ B, leading to increased transcription of the E3 ubiquitin-ligase, muscle RING-finger protein-1 (MuRF1). Another ligase, Atrogin1 (also known as MAFbx), is up-regulated by mitogen-activated protein kinase (MAPK) p38, while both ligases are up-regulated by forkhead box (FOXO) transcription factors. However, phosphorylated AKT blocks the transcriptional up-regulation of Atrogin1 and MuRF1 by inhibiting FOXO1, while phosphorylated mTORC1 inhibits the up-regulation of Atrogin1 directly. Myostatin also increases protein degradation and decreases protein synthesis by activating MAPKs and the SMAD complex, and by inhibiting PI3K. In addition, myostatin inhibits the myogenic program, thus resulting in a decrease of myoblast proliferation.

**Figure 2. Schematic representation of (A) the location of costameres within a skeletal muscle fiber and (B) the proteins that constitute the costamere.** Costameres are protein complexes circumferentially aligned along the length of the muscle fiber that connect peripheral myofibrils at the Z-disks to the sarcolemma and beyond to the extra-cellular matrix (ECM). The costamere comprises a dystrophin/glycoprotein complex and a focal adhesion complex (FAC), which includes the integrin-associated tyrosine kinase focal adhesion kinase (FAK). Fig. 2B modified from (Fluck et al., 2002) with permission.

**Figure 3. Breakdown of the protein fragment via the ubiquitin proteasome pathway.** Multiple ubiquitin (Ub) molecules form a polyubiquitin chain in a process involving the Ub-activating (E1), Ub-conjugating (E2), and Ub-ligating (E3) enzymes. The targeted protein fragment is then selected for degradation, or “tagged”, via the covalent attachment of the polyubiquitin chain. The tagging enables the 19S (PA700) module to recognize the protein fragment, so that it can be further degraded by the 20S core into oligopeptides after it has been de-ubiquitinated and the Ub molecules released recycled. Adapted from (Milacic, Dou, 2009) with permission.

Figure 1




Figure 2A




Figure 2B




Figure 3

